Teligent's Post-Sale Drug Recall Puts Its Ch. 11 Plan In Doubt
The Chapter 11 plan for the generic-drug maker once known as Teligent Inc. was thrown into doubt Friday after a bankruptcy court ruled that the company owes a refund for drugs it sold...To view the full article, register now.
Already a subscriber? Click here to view full article